Marinomed Biotech said that it has submitted an MAA via the decentralized marketing authorization procedure for a xylometazoline decongestant nasal spray formulated with the company’s Carragelose red algae extract. The company currently markets a range of non-prescription nasal sprays based on Carragelose, including Coldamaris; the xylometazoline spray will be its first prescription product if approved.
According to Marinomed, it has already signed marketing agreements with two partners for the new product, and expects the nasal spray to launch in 2021/22 in multiple EU markets. The company recently announced marketing agreements with Fidia Farmaceutici in Italy and Sanova Pharma in Austria for Carragelose based nasal sprays.
Marinomed CEO Andreas Grassauer commented, “With this decongestant nasal spray, we are expanding our successful Carragelose product range by including a non-prescription drug for the first time. This will give many people in Europe access to the advantages of Carragelose as a broad-spectrum virus blocker. As a company, we are strengthening our presence in the important market for decongestant nasal sprays.”
The company noted that independent studies have shown that low doses of Carragelose can prevent replication of the SARS-CoV-2 virus and that in vitro and clinical studies have shown that the seaweed extract has activity against a range of viruses, including influenza A, several coronaviruses, and respiratory syncytial virus. In April 2020, Marinomed announced plans for a Phase 1 study of a new Carragelose inhalation solution for the treatment of pneumonia associated with COVID-19.
Read the Marinomed press release.
